IRIST

Home

News

COST Meetings

STSM

Document & Forms

Related Congresses

Activity of WG1

Activity of WG2

Activity of WG3

Activity of WG4

Activity of WG5

Login | Register"

Meetings

Report of trainining school Mainz - September 2009	6th MC meeting, barcelona Oct'2009	5th MC meeting, Nantes May'2009
1st TARCC meeting, Nantes, May 2009	4th MC and WG meeting, Munich Oct'2008	3rd MC and WG meeting, Krakow June'2008
2nd MC meeting, London Dec'2007	1st MC meeting, Copenhagen Oct'2006

3rd MC and WG meeting, Krakow June'2008

3rd meeting in Krakow (PL), June 24 and 24. All information and details can be obtained in the COST-BM0607 website "Documents & Forms".

COST BM0607 Krakow Meeting Final Programme 20.06.08.doc

COST BM0607 Krakow MC Meeting Minutes.doc

Aloj L. Biological and clinical rationale for the development of CCK2-gastrin receptor binding ligands for PRRT.pdf

Barbet J. ARRONAX a new high-energy, high-intensity cyclotron for targeted radionuclide therapy in Europe.pdf

Barnard P. Diamide macrocycles potential bifunctional ligands for 64Cu, 68Ga and 99mTc.pdf

Behe M. Upregulation of gastrin and somatostatin receptor after irradiation.pdf

Boerman OC. Pretargeted ImmunoPET imaging of CEA-expressing tumors using a 68Ga-peptide.pdf

Breeman W. Radiochemical limitations in studies of receptor-mediated processes.pdf

Burchardt C. New 68Ga-labelled amino acids.pdf

Costa G. Targeted radionuclide therapy.pdf

Cremonesi M. Red marrow dosimetry.pdf

Cremonesi M. Zevalin dosimetry.pdf

Decristoforo C. Three generations of minigastrin derivatives.pdf

Glating G. RIT and Leukaemia dosimetry and modelling.pdf

Haubner R. Radiometallated RGD-peptides.pdf

Hermann P. Ligand design for radiometal complexation.pdf

Hindorf C. Dosimetry from patient to cell.pdf

Holger S. New versatile bifunctional chelate agents for Cu radiopharmaceuticals.pdf

Hubalewska-Dydejczyk A. Endocrine neoplasms-searching for new therapy.pdf

Isidoro J. Dosimetry in Coimbra.pdf

Laznickova A. Possible approaches to reduce renal radioactivity retention.pdf

Ljungberg M. Patient specific dosimetry.pdf

Maina T. Truncated MGs for targeting CCK2 with 99mTc. Comparison with 99mTcDemogastrin2.pdf

Majkowska A. Scandium-47 complexes as precursors for therapeutic.pdf

Melis M. Non-uniform distribution of radiolabelled peptides in xenografts in vivo.pdf

Mertens J. Radionuclide therapy with 2-131I-D-Phenylalanine in mice.pdf

Meyer GJ. Synthesis, analysis of 2- and 4- 211At-Phenylalanine uptake in glioma cells.pdf

Morelli G. Radiolabeled peptide containing supramolecular aggregates for selective delivery of therapeutics.pdf

Mullen G. Selective killing of hypoxic tumour cells with Cu-64-ATSM potential for hypoxia-selective radionuclide therapy.pdf

Peitl. Improved metabolic stability and pharmacokinetics of 111InDOTA-gastrin conjugates.pdf

Pszona S. New descriptors of radiation quality based on nanodosimetry.pdf

Ridone A. Biokinetic and radiopharmaceutical studies.pdf

Roesch F. High specific activities of therapeutic radiolanthanides following neutron capture nuclear reactions.pdf

Sosabowski J. SPECT imaging of CCK-2 receptors.pdf

Tolmachev V. Improving the biodistribution of anti-HER2 Affibody molecules by chelator engineering.pdf

Tuerler A. Production of n.c.a. radionuclides for therapy at TUM.pdf

Wild D. Alpha vs beta targeted radiotherapy in a GRP-receptor positive mouse xenografts.pdf

COST BM0607 Krakow meeting list of participants.pdf

Home | News | Project | Meetings | Board | STSM | Documents & Forms | Publications | Related Congresses | Isotopes | Activity of WG1 | Activity of WG2 | Activity of WG3 | Activity of WG4 | Activity of WG5 | Irist

© Copyright 2008 IRIST. All rights reserved.

Last update on 15/07/2010 - 01:23